Katie Boog - Academia.edu (original) (raw)

Papers by Katie Boog

Sexually Transmitted Infections, Jun 1, 2017

Journal of Prescribing Practice, 2021

Although often transient, side effects are the most common reason for individuals to discontinue ... more Although often transient, side effects are the most common reason for individuals to discontinue contraception. The evidence to prove causality is limited, as is evidence-based guidance on how to manage these side effects. This article summarises the available evidence. For individuals who have new or worsening acne on progestogen-only contraception (POC), switching to combined hormonal contraception (CHC) is likely to improve their skin. Continuous or extended CHC use may be beneficial for individuals with premenstrual mood change, and for those who experience headaches in the hormone-free interval. Unpredictable bleeding patterns on POC are common. Injectable users can try reducing the interval between injections to 10 weeks. Implant, injectable or Intrauterine system users can be offered a 3-month trial of a combined oral contraceptive pill (COC). CHC and POP users with unpredictable bleeding may benefit from switching to an alternative preparation.

Obstetrics, Gynaecology & Reproductive Medicine, 2021

Abstract Long-acting reversible contraception (LARC) is the collective name for intrauterine cont... more Abstract Long-acting reversible contraception (LARC) is the collective name for intrauterine contraception (copper intrauterine devices and levonorgestrel intrauterine systems) and the subdermal contraceptive implant . LARC methods are highly effective, require minimal user effort and do not require regular healthcare appointments; however the insertion and removal procedures can only be undertaken by clinicians trained to do so. The progestogen-only subdermal implant is the most effective method of reversible contraception in the United Kingdom and is licensed for 3 years. The copper intrauterine device is the most effective non-hormonal method of contraception. These devices are licensed for five or 10 years and can also be used as emergency contraception . The levonorgestrel intrauterine systems (LNG-IUS) are licensed for 3, 5, or 6 years. The Mirena LNG-IUS is also licensed for use in treating heavy menstrual bleeding and for endometrial protection as part of hormone replacement therapy.

Journal of Prescribing Practice, 2020

Although fertility naturally declines with age, women who do not wish to become pregnant require ... more Although fertility naturally declines with age, women who do not wish to become pregnant require contraception until menopause. The safety profile for contraception in women over 40 is different to that of younger women, due to an increased background risk of co-morbidities such as venous thromboembolism, osteoporosis and breast cancer. Conversely, contraception may alleviate or mask symptoms of perimenopause, such as vasomotor symptoms or problematic periods, conferring additional non-contraceptive benefits to women in this age group. For these reasons, the risk-benefit ratio for women over 40 using contraception is different to that of younger women and requires specific consideration when working with women to choose a suitable method of contraception.

BMJ Sexual & Reproductive Health, 2019

IntroductionReduced funding to contraceptive services in the UK is resulting in restricted access... more IntroductionReduced funding to contraceptive services in the UK is resulting in restricted access for women. Pharmacists are already embedded in sexual and reproductive health (SRH) care in the UK and could provide an alternative way for women to access contraception. The aim of this study was to determine the views of UK contraception providers about community pharmacist-led contraception provision.MethodsAn anonymous questionnaire was distributed to healthcare professionals at two UK SRH events, asking respondents about: (1) the use of patient group directions (PGDs) for pharmacist provision of oral contraception (OC); (2) the sale of OC as a pharmacy medicine or general sales list medicine; (3) the perceived impact of pharmacy provision of OC on broader SRH outcomes; and (4) if other contraceptive methods should be provided in pharmacies.ResultsOf 240 questionnaires distributed, 174 (72.5%) were returned. Respondents largely supported pharmacy-led provision of all non-uterine met...

BMJ sexual & reproductive health, Oct 1, 2018

We would like to share with the readers an interesting case of a cervical perforation by the thre... more We would like to share with the readers an interesting case of a cervical perforation by the threads of an intrauterine device (IUD). Our patient was a multiparous woman in her 40s who attended for removal of her IUD due to dysmenorrhoea, having had a TT380-Slimline inserted by her general practitioner 5 years previously. She denied any post-coital bleeding or dyspareunia and was otherwise well with no history of gynaecological procedures, abnormal smears or pelvic infections. On examination, the threads of the IUD were protruding from the anterior lip of her cervix, approximately 10 mm from the ectocervical os at the 1 o’clock position (figure 1). Figure 1 IUD threads perforating the anterior cervix We were concerned that the frame of the IUD might have perforated the uterus or the cervix. We therefore performed …

BMJ sexual & reproductive health, Jan 10, 2018

This quality improvement project reports a provider perspective of service-level challenges assoc... more This quality improvement project reports a provider perspective of service-level challenges associated with implementing integrated sexual and reproductive healthcare (SRH) services. Funding constraints and competitive tendering have led to rapid remodelling of sexual health services (SHS) in England,1 2 with multiple contractual changes causing integration and splitting of many components of SRH care, as well as changes to service management and delivery.2 3 In January 2014, an integrated SHS was launched in Leicestershire, UK, providing Levels 1–3 contraception and genitourinary medicine (GUM) services and SRH promotion and prevention. The SHS serves a population of 1.1 million over 900 square miles, seeing approximately 50 000 patients per year. Leicester City, Leicestershire County and Rutland County Councils co-commissioned the service and the contract was awarded to Staffordshire & Stoke on Trent Partnership NHS Trust. This saw the transfer of GUM services from an acute hospital setting to join community contraceptive services, merging staff from both departments. HIV treatment, abortion care and vasectomies were no longer provided within the SHS.4 The new amalgamated service adopted a WI system for all patients. Reception staff asked patients their reason for attendance and placed notes in time order in one tray for all …

BMJ Sexual & Reproductive Health

BMJ SRH, 2018

This quality improvement project reports a provider perspective of service-level challenges ass... more This quality improvement project reports
a provider perspective of service-level
challenges associated with implementing
integrated sexual and reproductive
healthcare (SRH) services. Funding
constraints and competitive tendering
have led to rapid remodelling of sexual
health services (SHS) in England,1 2 with
multiple contractual changes causing inte-
gration and splitting of many components
of SRH care, as well as changes to service
management and delivery.2 3
In January 2014, an integrated SHS
was launched in Leicestershire, UK,
providing Levels 1–3 contraception and
genitourinary medicine (GUM) services
and SRH promotion and prevention. The
SHS serves a population of 1.1million
over 900 square miles, seeing approxi-
mately 50000 patients per year. Leicester
City, Leicestershire County and Rutland
County Councils co-commissioned the
service and the contract was awarded to
Staffordshire & Stoke on Trent Partner-
ship NHS Trust. This saw the transfer
of GUM services from an acute hospital
setting to join community contraceptive
services, merging staff from both depart-
ments. HIV treatment, abortion care and
vasectomies were no longer provided
within the SHS.4

BMJSRH, 2019

Introduction Reduced funding to contraceptive services in the UK is resulting in restricted acce... more Introduction Reduced funding to contraceptive
services in the UK is resulting in restricted access
for women. Pharmacists are already embedded
in sexual and reproductive health (SRH) care in
the UK and could provide an alternative way
for women to access contraception. The aim
of this study was to determine the views of
UK contraception providers about community
pharmacist-led contraception provision.
Methods An anonymous questionnaire was
distributed to healthcare professionals at two
UK SRH events, asking respondents about: (1)
the use of patient group directions (PGDs) for
pharmacist provision of oral contraception (OC);
(2) the sale of OC as a pharmacy medicine or
general sales list medicine; (3) the perceived
impact of pharmacy provision of OC on broader
SRH outcomes; and (4) if other contraceptive
methods should be provided in pharmacies.
Results Of 240 questionnaires distributed,
174 (72.5%) were returned. Respondents
largely supported pharmacy-led provision of
all non-uterine methods of contraception,
excluding the contraceptive implant. Provision
of the progestogen-only pill by PGD was most
strongly supported (78% supported initiation).
Respondents felt that the use of bridging
(temporary) contraception would improve
(103/144, 71.5%), use of effective contraception
would increase (81/141, 57.4%), and
unintended pregnancies would decline (71/130,
54.6%); but that use of long-acting reversible
contraception would decrease (86/143, 60.1%).
Perceived barriers included pharmacists’ capacity
and competency to provide a full contraception
consultation, safeguarding concerns, and
women having to pay for contraception.
Conclusions UK SRH providers were largely
supportive of community pharmacy-led
provision of contraception, with training and
referral pathways being required to support
contraception delivery by pharmacists.